New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection

Marion G Peters1, Stephen Locarnini1

  • 1Dr Peters is a professor of medicine and chief of hepatology research in the Department of Medicine at the University of California in San Francisco, California. Dr Locarnini is a professor of microbiology and immunology at the University of Melbourne and is director of the WHO Regional Reference Laboratory for Hepatitis B within the Victorian Infectious Diseases Reference Laboratory at the Doherty Institute in Melbourne, Australia.

Insights

New treatments for chronic hepatitis B (CHB) are in development, targeting the hepatitis B virus (HBV) life cycle and immune response. Understanding CHB phases and HBV life cycle is key for effective new therapy combinations.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) impacts over 350 million globally, being a leading cause of liver cancer.
  • Current CHB therapies manage the condition but do not offer a cure.
  • CHB affects 2-3 million in the U.S. alone.

Purpose of the Study:

  • To review the various phases of CHB and the hepatitis B virus (HBV) life cycle.
  • To discuss the mechanisms of action for novel CHB therapeutic molecules.
  • To explore potential combination strategies for new CHB therapies across different disease phases.

Main Methods:

  • Review of preclinical and phase 2 studies for over 30 new molecules targeting HBV.
  • Analysis of HBV life cycle and host immune response pathways.
  • Examination of therapeutic strategies for CHB management.

Main Results:

  • Over 30 novel molecules are under investigation, targeting distinct aspects of HBV replication and host immunity.
  • Understanding of HBV lifecycle and CHB disease progression is crucial for therapeutic development.
  • Potential for combination therapies exists to improve CHB treatment outcomes.

Conclusions:

  • Novel therapeutic approaches for CHB are emerging, focusing on specific viral and host targets.
  • A comprehensive understanding of CHB phases and HBV biology is essential for advancing treatment.
  • Future CHB treatment may involve combination therapies tailored to disease stage.

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.6K